Quarterly report pursuant to Section 13 or 15(d)

Document And Entity Information

Document And Entity Information - shares
3 Months Ended
Nov. 30, 2017
Jan. 16, 2018
Document And Entity Information [Abstract]    
Entity Registrant Name ARTELO BIOSCIENCES, INC.  
Entity Central Index Key 0001621221  
Trading Symbol artl  
Current Fiscal Year End Date --08-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   11,472,302
Document Type 10-Q/A  
Document Period End Date Nov. 30, 2017  
Amendment Flag true  
Amendment Description


Artelo Biosciences, Inc. (the "Company") is filing this Amendment No. 1 on Form 10-Q/A (this "Amendment") to its Quarterly Report on Form 10-Q for the period ended November 30, 2017, which was originally filed on January 16, 2018 (the "Original Filing"). The purpose of this Amendment is to amend and restate Part I -Controls and Procedures of Item 4 solely to (i) include the information required by Item 307 of Regulation S-K, which was inadvertently omitted in the Original Filing; (ii) revise the disclosure to correctly reflect management’s conclusion that the Company’s disclosure controls and procedures were effective as of November 30, 2017; and (iii) update Part II - Item 6 - Exhibits to reflect the exhibits filed with this Amendment. As required by Rule 13a-15(b) promulgated under the Securities Exchange Act of 1934, as amended, the Company’s management evaluated, with the participation of its chief executive officer (its principal executive officer, principal financial officer and principal accounting officer), the effectiveness of its disclosure controls and procedures as of November 30, 2017 before filing the Original Filing. Based on that evaluation, the Company’s management concluded that its disclosure controls and procedures were effective as of such date.

Other than as set forth herein, this Amendment does not modify or update the Original Filing in any way, and the parts or exhibits of the Original Filing which have not been modified or updated are not included in this Amendment. This Amendment continues to speak as of the date of the Original Filing and the Company has not updated the disclosure contained herein to reflect events that have occurred since the filing of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Company’s other filings made with the Securities and Exchange Commission since the filing of the Original Filing, including amendments to those filings, if any.

Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1